News - oNKo-innate

12 July 2024 Chemmunity: Sticking Immune Biology together with Molecular Glue Read More

Immunotherapy for cancer causes immune cells to attack a tumor

26 June 2024 What is Immunotherapy for Cancer and Why is it So Important? Read More

29 February 2024 Firing Up the Cold Tumor: A Major Obstacle in Cancer Therapy Read More

a white macrophage cell on a red background secretes blue and yellow cytokines

28 February 2024 An Introduction to Cytokine Therapy: Your Questions Answered Read More

10 September 2024 Dr. Bruce Fischer appointed as Chief Medical Officer Read More

7 February 2024 Imran House and Junyun Lai featured on the Synthego CRISPR cuts Podcast Read More

3 January 2024 oNKo-innate Experts Present Posters on Target Discovery and Cytokine Therapy at International Conferences Read More

2 January 2024 oNKo-001: A reduced potency IL-12 Fc fusion protein with enhanced therapeutic index Read More

Schematic outline of oNKo-Innate NK cell screening platform

2 January 2024 Systematic target discovery in human NK cells using functional genomics Read More

22 December 2023 oNKo-innate Receives Pipeline Accelerator Award Read More

16 October 2023 Richard Berry promoted to Vice President, Biotherapeutics Read More

9 October 2023 Joe Cursons promoted to Vice President, Computational Biology Read More

22 September 2023 Iva Nikolic promoted to Chief Technology Officer Read More

27 October 2021 oNKo-innate named Australian Emerging Company of the Year 2021 Read More

10 July 2020 The cancer–natural killer cell immunity cycle Read More

10 June 2020 Monash University and oNKo-innate Announce Research Partnership Read More

23 April 2020 Onko-Innate, Gilead, Kite Work On NK Cancer Immunotherapies Read More

22 April 2020 Immunotherapy biotech scores Gilead partnership Read More